|Traded as||NASDAQ: PTCT|
|Headquarters||South Plainfield, New Jersey, United States|
PTC Therapeutics is a pharmaceutical company focused on the development of small molecule, orally administered treatments for orphan diseases. As of September 2013[update], PTC was headquartered at 100 Corporate Court, South Plainfield, New Jersey.:cover
As of September 2009, PTC has entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system disease targets. Roche said use of PTC's GEMS technology for the identification of small molecules "will enable Roche to address important disease mechanisms that were intractable with conventional approaches." 
- Bhutta, Sunya (December 2013). "Biopharma Blossoming in the Garden State". Biobusiness. Gen. Eng. Biotechnol. News 33 (21). p. 15.
- "PTC Therapeutics, Inc.". edgar archives. 10-Q. USSEC. September 30, 2013. Retrieved January 5, 2014.
- Hamed SA (2006). "Drug evaluation: PTC-124--a potential treatment of cystic fibrosis and Duchenne muscular dystrophy". IDrugs : the investigational drugs journal 9 (11): 783–9. PMID 17096300.
- Schneider, Ilene (2009). "Firm Aims to Regulate RNA in Rare Diseases". Genetic Engineering & Biotechnology News 29 (8): 14. Retrieved 2009-04-25.
|This pharmacology-related article is a stub. You can help Wikipedia by expanding it.|